Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways

Kim R. Bridle, Claudia Popa, Maelle L. Morgan, Amy L. Sobbe, Andrew D. Clouston, Linda M. Fletcher, Darrell H. G. Crawford – 29 September 2009 – Hepatic stellate cell transdifferentiation, epithelial‐mesenchymal cell transition, and the ductular reaction each contribute to the development of hepatic fibrosis in cholestatic liver diseases. Inhibitors of mammalian target of rapamycin have antifibrotic properties.

The use of preoperative nutritional interventions to protect against hepatic ischemia‐reperfusion injury

Tessa M. van Ginhoven, James R. Mitchell, Marielle Verweij, Jan H. J. Hoeijmakers, Jan N. M. Ijzermans, Ron W. F. de Bruin – 29 September 2009 – Preoperative fasting was introduced in the 19th century to reduce the risk of aspiration pneumonia while patients were under general anesthesia. During the last decades, the value of preoperative fasting has been questioned, and more liberal guidelines have been proposed, such as the use of preoperative carbohydrate‐rich drinks.

Mesenchymal stem cells as immunomodulators after liver transplantation

Felix C. Popp, Philipp Renner, Elke Eggenhofer, Przemyslaw Slowik, Edward K. Geissler, Pompiliu Piso, Hans J. Schlitt, Marc H. Dahlke – 29 September 2009 – Mesenchymal stem cells (MSCs) are promising candidate cells for immunomodulation therapy that are currently being tested in the preclinical and clinical setting. MSCs suppress the immune response in a variety of in vitro and disease models and may thus be of benefit for patients suffering from autoimmune disorders or transplant rejection.

Acute liver failure at 26 weeks' gestation in a patient with sickle cell disease

Mara Greenberg, Tami J. Daugherty, Arvand Elihu, Ravi Sharaf, Waldo Concepcion, Maurice Druzin, Carlos O. Esquivel – 29 September 2009 – Orthotopic liver transplantation (OLT) for acute liver failure (ALF) during pregnancy is an uncommon occurrence with variable outcomes. In pregnancy‐related liver failure, prompt diagnosis and immediate delivery are essential for a reversal of the underlying process and for maternal and fetal survival. In rare cases, the reason for ALF during pregnancy is either unknown or irreversible, and thus OLT may be necessary.

Therapeutic RNA manipulation in liver disease

Thomas A. Kerr, Nicholas O. Davidson – 29 September 2009 – Posttranscriptional regulation of gene expression is increasingly recognized as a model for inherited and acquired disease. Recent work has expanded understanding of the range of mechanisms that regulate several of these distinct steps, including messenger RNA (mRNA) splicing, trafficking, and/or stability. Each of these pathways is implicated in disease pathogenesis, and each represents important avenues for therapeutic intervention.

Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up‐to‐seven criteria

Francesco D'Amico, Myron Schwartz, Alessandro Vitale, Parissa Tabrizian, Sasan Roayaie, Swan Thung, Maria Guido, Juan del Rio Martin, Thomas Schiano, Umberto Cillo – 29 September 2009 – The up‐to‐seven (Up‐to‐7) criteria [with 7 being the sum of the size and number of tumors for any given hepatocellular carcinoma (HCC)] have been recently proposed to identify potential candidates for liver transplantation (LT) among patients exceeding the Milan criteria.

Liver grafts from donors with central nervous system tumors: A single‐center perspective

Randeep Kashyap, Charlotte Ryan, Rajeev Sharma, Manoj K. Maloo, Saman Safadjou, Maureen Graham, David Tretheway, Ashokkumar Jain, Mark Orloff – 29 September 2009 – Traditionally, patients who die with a malignancy have been excluded from donation. However, it has become a common practice to accept organs from donors that have low‐grade tumors or tumors with low metastatic potential. The aim of this study was to analyze our experience with the use of liver grafts from donors with central nervous system (CNS) tumors.

Subscribe to